InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,476.00
(
1.10%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.97
(
0.00%
)
Bitcoin
61,929.21
(
-0.24%
)
Post# of 871
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

The Lawman

Send PM Follow Ignore
Followers 10
Posts 504
Boards Moderated 0
Alias Born 04/20/2016

The Lawman

Re: None

Wednesday, 09/22/2021 12:25:53 PM

Wednesday, September 22, 2021 12:25:53 PM

Post# of 871
Gilead announced results from a double-blind Phase 3 clinical trial which showed that early administration of Remdesivir reduced hospitalizations for Covid-19 by 67%.

More importantly for Matinas Biopharma (MTNB), Gilead also announced it is developing a novel oral treatment for Remdesivir, and hoped to file an INDA with the FDA in early 2022.

Given that, according to Matinas' CEO, Jerry Jabbour, the NIH placed Matinas' LNC version of Remdesivir at the top of the queue, it would be fair to infer that this is the "novel oral treatment" for Remdesivir announced by Gilead.

If so, MTNB will be off to the races when the INDA application is filed with the FDA in early 2022.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent MTNB News
More MTNB News
InvestorsHub NewsWire

North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM

Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM

Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM

SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM

Start posting your company's news
Only $200 per official company press release!